# Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)

> **NCT01256775** · PHASE2 · COMPLETED · sponsor: **NicOx Research Institute S.r.l.** · enrollment: 442 (actual)

## Conditions studied

- Intermittent Claudication

## Interventions

- **DRUG:** NCX-4016
- **DRUG:** NCX4016 placebo

## Key facts

- **NCT ID:** NCT01256775
- **Lead sponsor:** NicOx Research Institute S.r.l.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 442 (ACTUAL)
- **Last updated:** 2011-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01256775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01256775, "Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01256775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*